ERBB2 and triple-negative breast carcinoma: Lipid deregulation might be more severe in triple-negative breast cancer (TNBC) that does not respond well to hormone or anti-HER2 therapies [46,47], and targeted evaluation in TNBC will be valuable in future studies since immunotherapy is becoming an increasingly valuable alternative for the treatment of TNBC patients [48].